Ceritinib is an anaplastic lymphoma kinase (ALK) inhibitor used for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC). This BCS class IV drug is developed by Novartis and traded under the name Zykadia. To date two forms [Form A (marketed form) and B] of ceritinib are disclosed in international patent application US 2013/0274279 A1. However, the crystal structure and insight into any solid form of this compound are not available in the literature. In order to achieve better physicochemical properties compared to known solid forms of this compound, novel polymorph identification is chosen as one of the challenging paths to address the issue. In our comprehensive polymorph screening, including in silico and experimental investigations, we discovered three novel solid forms of ceritinib. Out of these three solid forms, two are neat (Form 1 and Form 3) and the remaining one is a hydrate (Form 2). All synthesized forms are further characterized by powder X-ray diffraction, differential scanning calorimetry, and Fourier transform infrared spectroscopy. It is interesting to note that the discovery of this hydrate is in sync with the prediction done using COSMO-RS theory (COSMOthermX software). The current article includes the first single crystal structure of ceritinib Form 1. All forms (Form 1, 2, and 3) of ceritinib are subjected to physicochemical property evaluation like solubility in buffers with a pH range of 1–7, dissolution, and stability. In aqueous solutions and pH 4.5 (acetate buffer), the solubility of Form 2 and 3 is high compared to Form 1, whereas in 0.1 N HCl and 0.01 N HCl Form 1 has a higher solubility compared to Forms 2 and 3. A six-month stability study indicates that all forms (Forms 1, 2, and 3) are stable in ICH stability conditions like accelerated (40 °C ± 2 °C, 75% RH ± 5% RH), long-term (25 °C ± 2 °C, 60% RH ± 5% RH), and low temperature (2–8 °C) conditions. A thorough polymorph screening protocol, including in silico prediction, single crystal structure, and physicochemical properties of different forms and structure property correlations for ceritinib are enlightened in the current paper.

The intent of this work was to study the effect of polymorphism on dissolution properties and to apply several methods to evaluate the dissolution profiles of immediate-release tablets containing alpha (α) and beta (β) forms of eletriptan hydrobromide (EH). The polymorphs were characterized by X-ray diffraction (XRD), differential scanning calorimetry (DSC), and diffuse reflectance infrared Fourier transform spectroscopy (DRIFTS). The dissolution conditions were USP Apparatus 2 (paddle) with 900 mL of 0.1 N HCl medium at a rotation speed of 100 rpm. The dissolution profiles were compared using model-independent, model-dependent, and statistical methods. In the model-independent approaches, dissolution efficiency (DE), mean dissolution time (MDT), difference factor (f 1 ), and similarity factor (f 2 ) were evaluated. A statistical assessment of DE data was performed using ANOVA and the t-test. Dissolution kinetics was determined using model-dependent approaches in which nine drug release mathematical models were evaluated. The dissolution profile of the α formulation was best represented by the Weibull model, and the β formulation by the Korsmeyer-Peppas model. The calculated fit factors infer that the two tablet formulations are similar with minor differences. Statistical and model-dependent approaches demonstrate that there may be a difference in the drug release mechanism.